AA
MYGN icon

Antipodean Advisors’s Myriad Genetics MYGN Stock Holding History

Antipodean Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-287,000
Closed -$6.02M – 25
2013
Q4 		$6.02M Buy
287,000
+149,000
+108% +$3.77M 0.52% 23
2013
Q3 		$3.24M Buy
+138,000
New +$3.92M 0.34% 28

Other funds holding MYGN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Tiger Global Management
Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Antipodean Advisors's MYGN Position: Q1 2014 in Review

Antipodean Advisors sold out of Myriad Genetics (MYGN) in Q1 2014, closing a stake of 287,000 shares — an estimated $6.02M sold.

Antipodean Advisors first reported a position in MYGN in Q3 2013 and held it in 2 quarters. The position peaked at $6.02M in Q4 2013. 280 funds tracked by Wall St. Rank hold MYGN as of Q1 2014.

  • Antipodean Advisors reported no remaining Myriad Genetics position as of Q1 2014 after selling out during the quarter.
  • Antipodean Advisors sold 287,000 Myriad Genetics shares in Q1 2014, an estimated $6.02M.
  • Antipodean Advisors first reported a position in Myriad Genetics in Q3 2013 and held it in 2 quarters.
  • Antipodean Advisors's Myriad Genetics position peaked at $6.02M in Q4 2013.
  • 280 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2014.

Based on Antipodean Advisors's 13F filing for Q1 2014, filed 15 May 2014.